Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.

Abstract: A hand held device for land management is described for a user of the device to provide agricultural information relating to a field, wherein the agricultural information includes information on at least one crop. A transmitter of the device transmits information including the agricultural information relating to the field. A receiver of the device receives agricultural data that includes best practices for the growing of the at least one crop. A processing unit of the device determines agricultural management information on the basis of the agricultural data. An output unit of the device outputs the agricultural management information to the user of the device.

Abstract: The present invention covers quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Abstract: The invention relates to prolyl endopeptidase (PREP) inhibitors which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).

Abstract: The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.

Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Abstract: A method of predetermining the time profile of a contrast agent concentration at a vessel position is provided in the context of contrast agent-enhanced MRI of a region of interest only during the initial flooding-in phase of the contrast agent into the vessel situated in the region of interest. The method includes establishing a broadening of a contrast agent bolus profile according to the equation ?W=W2?W1 wherein W1 is a first width of the contrast agent bolus profile at a first vessel position and W2 is a second width of a contrast agent concentration profile at a second vessel position within the region of interest. The broadening is established by determining at least one flow parameter which is dependent on at least one blood flow property of the patient at a third vessel position thereof and which correlates with the broadening of the contrast agent profile.

Abstract: A catheter including at least one distal opening positioned at or near the distal end and at least one proximal opening near the proximal end and proximal to the at least one distal opening is described. The catheter may be configured for delivering at least a first fluid through the at least one distal opening to a central circulation system of a patient and delivering at least a second fluid through the at least one proximal opening to a peripheral circulation system of the patient.

Abstract: A fluid injection system that includes an injector head having a syringe for delivering a fluid to a patient; a mounting structure pivotally connected to the injector head and configured to support the injector head above a surface; and a control system operationally coupled to the injector head for controlling an injection procedure is disclosed. The fluid injection system is provided with various sensors to control various aspects of the fluid injection system, such as the establishment of a reference plane, the determination of a tilt angle of the injector head, and the determination of a temperature of an actuation system of the injector head.

Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

Abstract: The invention relates to the technical field of the herbicides and/or plant growth regulators. Specifically, the invention primarily relates to novel substituted isothiazolopyridones, and compositions comprising said novel substituted isothiazolopyridones. Further, the present invention relates to processes for the preparation said novel substituted isothiazolopyridones and their use as herbicides and/or plant growth regulators.

Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Abstract: Conjugate of a binder having formula: (A) wherein stands for a binder, Z? stands for a linker and D stands for an active component of Formula (I): and its use as pharmaceuticals.

Abstract: An adapter for releasably attaching a syringe to an injector. The adapter comprises a mounting mechanism positioned at a rear end of the adapter to mount the adapter in a desired position relative to a front wall of the injector; and a syringe carrier section adapted to seat at least a portion of the syringe. The syringe carrier section defines a first opening on a top thereof to allow placement of the syringe therein from the top and a second opening in a rear section thereof to allow the drive member of the injector to communicate forward force to the plunger. A cover portion extends over a rearward end of the first opening and has a first end configured to abut the flange of the syringe when the syringe is positioned within the syringe carrier section.

Abstract: The invention relates inter alia to novel compounds of the general formula (I) in which the A1-A4, T, W, Q, R1 and B1-B4 radicals are each as defined in the description. Also described are processes for preparing the compounds of the formula (I). The inventive compounds are especially suitable for controlling insects, arachnids and nematodes in agriculture, and ectoparasites in veterinary medicine.

Abstract: A bladder syringe for a fluid delivery system includes a cylindrical body, a cap-bladder assembly, a plunger element disposed in the cylindrical body, and a mounting assembly to secure the cap-bladder assembly to the cylindrical body. The cylindrical body has a distal end and a proximal end and defines a throughbore. The cap-bladder assembly is adapted for connection to the distal end of the cylindrical body, and includes a cap body and a bladder. The cap body defines an interior cavity and a distal discharge conduit and is adapted to engage the distal end of the cylindrical body. A disc-shaped bladder is disposed within the interior cavity and typically includes a central membrane portion. The plunger element is disposed in the throughbore of the cylindrical body and is vented to enable evacuation of the space between the plunger element and the cap-bladder assembly in the cylindrical body.

Abstract: A pest monitoring system and associated method includes pest monitoring devices for placement at a site and generating a signal upon detection of a pest, and a pesticide dispensing unit including a reservoir housing a diluent and a pesticide module housing a pesticide. A computer device remotely disposed to the pest monitoring devices receives generated signals therefrom, analyzes environmental and historical factor data for the site to determine an amount and placement location of the pest monitoring devices for monitoring the site, and directs deployment of the pest control monitoring devices according to the analysis. The computer device also receives data from the pesticide dispensing unit including an amount or rate of the pesticide substance dispensed from the pesticide module, to form treatment having a concentration of the pesticide substance in the diluent, the treatment being dispensed from the pesticide dispensing unit to treat a detected pest at the site.